Lung preservation with Euro-Collins, University of Wisconsin, Wallwork, and low-potassium-dextran solution. Université++ Paris-Sud Lung Transplant Group.
Using isolated rat lungs, we compared prevention of ischemia-reperfusion injury provided by flushing the lungs with modified Euro-Collins solution (EC), University of Wisconsin solution (UW), low-potassium-dextran solution (LPD), or Wallwork solution (WA). After 4 hours' and 6 hours' cold ischemia, reperfusion injury was assessed on the basis of changes in filtration coefficients (Kfc) and pressure-flow curves, characterized by the slope of the curves (incremental resistance) and the extrapolation of this slope to zero flow (pulmonary pressure intercept [Ppi]). After 4 hours, Kfc and Ppi were higher with EC than with UW, LPD, and WA, and the incremental resistance was higher with EC and UW. After 6 hours, Kfc and incremental resistance Ppi were higher with LPD than with WA. Because ischemia-reperfusion injury is associated with decreased endothelial synthesis of prostacyclin and nitric oxide, we tested whether the addition of prostacyclin or the nitric oxide precursor L-arginine to WA would improve preservation. The Kfc and Ppi were lower with both treatments. In conclusion, ischemia-reperfusion injury was best prevented by using WA. The favorable effect of prostacyclin or L-arginine emphasizes the role played by endothelial dysfunction in ischemia-reperfusion injury.
Xiong
L
L
Centre Chirurgical Marie Lannelongue, Université Paris Sud, Le Plessis Robinson, France.
Mazmanian
M
M
Chapelier
A R
AR
Reignier
J
J
Weiss
M
M
Dartevelle
P G
PG
Hervé
P
P
D000241:Adenosine / Q000008:administration & dosage; D000418:Albumins / Q000008:administration & dosage*; D000493:Allopurinol / Q000008:administration & dosage; D000818:Animals; D001794:Blood Pressure; D002314:Cardioplegic Solutions / Q000008:administration & dosage; D002712:Chlorides / Q000008:administration & dosage*; D011464:Epoprostenol / Q000008:administration & dosage; D005978:Glutathione / Q000008:administration & dosage; D006982:Hypertonic Solutions / Q000008:administration & dosage*; D007036:Hypothermia, Induced; D066298:In Vitro Techniques; D007328:Insulin / Q000008:administration & dosage; D008168:Lung / Q000098:blood supply* / Q000503:physiopathology; D008170:Lung Compliance; D008297:Male; D008353:Mannitol / Q000008:administration & dosage*; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions; D009929:Organ Size; D017680:Potassium Compounds / Q000008:administration & dosage*; D011422:Propionates / Q000008:administration & dosage*; D011651:Pulmonary Artery / Q000503:physiopathology; D011887:Raffinose / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control*; D013997:Time Factors; D014655:Vascular Resistance
D000418:Albumins; D002314:Cardioplegic Solutions; D002712:Chlorides; C037096:Euro-Collins' solution; D006982:Hypertonic Solutions; D007328:Insulin; D019188:Organ Preservation Solutions; D017680:Potassium Compounds; D011422:Propionates; C055206:University of Wisconsin-lactobionate solution; C089639:Wallwork solution; C018369:potassium cardioplegic solution; D008353:Mannitol; D000493:Allopurinol; D011464:Epoprostenol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose